Aayoung Hong
YOU?
Author Swipe
View article: Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Table S1: Clinical characteristics of patients who donated MAPKi-sensitive/-naive and acquired MAPKi-resistant melanoma. Table S2: Genomic alterations, chromothripsis, and ecDNA-/CGR-amplicons detected in MAPKi-sensitive/-naive and acquire…
View article: Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Supplementary Figure S1. Associations of CGRs and ecDNAs with ploidy, expression, and enhancers. Supplementary Figure S2. Analysis of chromothripsis, ecDNAs, and CGRs in MAPKi-sensitive/-naïve versus -resistant melanoma. Supplementary Figu…
View article: Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Table S1: Clinical characteristics of patients who donated MAPKi-sensitive/-naive and acquired MAPKi-resistant melanoma. Table S2: Genomic alterations, chromothripsis, and ecDNA-/CGR-amplicons detected in MAPKi-sensitive/-naive and acquire…
View article: Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Supplementary Figure S1. Associations of CGRs and ecDNAs with ploidy, expression, and enhancers. Supplementary Figure S2. Analysis of chromothripsis, ecDNAs, and CGRs in MAPKi-sensitive/-naïve versus -resistant melanoma. Supplementary Figu…
View article: Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Supplementary Figure S1. Associations of CGRs and ecDNAs with ploidy, expression, and enhancers. Supplementary Figure S2. Analysis of chromothripsis, ecDNAs, and CGRs in MAPKi-sensitive/-naïve versus -resistant melanoma. Supplementary Figu…
View article: Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Table S1: Clinical characteristics of patients who donated MAPKi-sensitive/-naive and acquired MAPKi-resistant melanoma. Table S2: Genomic alterations, chromothripsis, and ecDNA-/CGR-amplicons detected in MAPKi-sensitive/-naive and acquire…
View article: Data from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Data from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Blocking cancer genomic instability may prevent tumor diversification and escape from therapies. We show that, after MAPK inhibitor (MAPKi) therapy in patients and mice bearing patient-derived xenografts (PDX), acquired resistant genomes o…
View article: Figure S8 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S8 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S8. BRAFi plus PARPi augment the cell-death predominant MEKi-addiction phenotype of MUTNRAS melanoma
View article: Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 175K, Catalogue of mechanisms and pathways analyzed and their results
View article: Figure S4 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S4 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S4. Caspase 3-independence of the cell-death predominant MAPKi-addiction phenotype
View article: Figure S5 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S5 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S5
View article: Figure S4 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S4 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S4
View article: Data from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Data from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fitness upon experimental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after a drug holiday. Here, we uncovered and therapeutically exploited the mech…
View article: Figure S6 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S6 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S6. AIF knockdown did not affect the slow-cycling predominant MAPKi-addiction phenotype
View article: Figure S8 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S8 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S8. BRAFi plus PARPi augment the cell-death predominant MEKi-addiction phenotype of MUTNRAS melanoma
View article: Figure S2 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S2 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S2
View article: Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity Open
Supplementary Table S2
View article: Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity Open
Supplementary Figures, Figure Legends, and Table Legends
View article: Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity Open
Supplementary Table S2
View article: Figure S3 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S3 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S3. Mitochondrial dysfunctions induced by MAPKi withdrawal in R-lines
View article: Figure S6 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Figure S6 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Figure S6
View article: Supplementary Table S4 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Supplementary Table S4 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity Open
Supplementary Table S4
View article: Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma Open
Table S1: Clinical characteristics of patients who donated MAPKi-sensitive/-naive and acquired MAPKi-resistant melanoma. Table S2: Genomic alterations, chromothripsis, and ecDNA-/CGR-amplicons detected in MAPKi-sensitive/-naive and acquire…
View article: Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Open
BRAF inhibitor (BRAFi) therapy leads to remarkable anti melanoma responses, but the initial tumor shrinkage is commonly incomplete, providing a nidus for subsequent disease progression. Adaptive signaling may underlie early BRAFi resistanc…
View article: Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Supplementary Table S1-S3
View article: Figure S2 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S2 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S2. Gene expression and signaling responses underlying the slow-cycling predominant, MAPKi-addiction phenotype
View article: Supplementary Table S5 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S5 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLSX file 12K, Accounting of frequencies of detecting core resistance pathway mechanisms
View article: Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity Open
Supplementary Table S3
View article: Figure S7 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Figure S7 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Open
Supplementary Figure S7. Effect of impairing DNA damage repair on the growth of slow-cycling predominant R-lines upon MAPKi withdrawal
View article: Supplementary Methods, References and Legends from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Supplementary Methods, References and Legends from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Open
Supplementary Methods, References and Legends